Washed microbiota transplantation stopped the deterioration of amyotrophic lateral sclerosis: The first case report and narrative review

Gaochen Lu; Quan Wen; Bota Cui; Qianqian Li; Faming Zhang

doi:10.7555/JBR.36.20220088

Volume 37 Issue 1

Jan. 2023

Turn off MathJax

Article Contents

Article Navigation > The Journal of Biomedical Research > 2023 > 37(1): 69-76

Gaochen Lu, Quan Wen, Bota Cui, Qianqian Li, Faming Zhang. Washed microbiota transplantation stopped the deterioration of amyotrophic lateral sclerosis: The first case report and narrative review[J]. The Journal of Biomedical Research, 2023, 37(1): 69-76. doi: 10.7555/JBR.36.20220088

Citation:

Gaochen Lu, Quan Wen, Bota Cui, Qianqian Li, Faming Zhang. Washed microbiota transplantation stopped the deterioration of amyotrophic lateral sclerosis: The first case report and narrative review[J]. The Journal of Biomedical Research, 2023, 37(1): 69-76. doi: 10.7555/JBR.36.20220088

Citation:

Gaochen Lu, Quan Wen, Bota Cui, Qianqian Li, Faming Zhang. Washed microbiota transplantation stopped the deterioration of amyotrophic lateral sclerosis: The first case report and narrative review[J]. The Journal of Biomedical Research, 2023, 37(1): 69-76. doi: 10.7555/JBR.36.20220088

PDF( 4668 KB)

Washed microbiota transplantation stopped the deterioration of amyotrophic lateral sclerosis: The first case report and narrative review

doi: 10.7555/JBR.36.20220088

Gaochen Lu^{1, 2},
Quan Wen^{1, 2},
Bota Cui^{1, 2},
Qianqian Li^{1, 2},
Faming Zhang^{1, 2, 3, 4
,
,}

1.
Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, China
2.
Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, Jiangsu 210011, China
3.
Department of Microbiotherapy, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu 211166, China
4.
National Clinical Research Center for Digestive Diseases, Xi'an, Shanxi 710032, China

Funds: This study was funded by the National Natural Science Foundation of China (Grant No. 81873548) and the Nanjing Medical University Fan Daiming Research Funds for Holistic Integrative Medicine.

More Information

Corresponding author: Faming Zhang, Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, 121 Jiang Jia Yuan, Nanjing, Jiangsu 210011, China. Tel: +86-25-56662093, E-mail: fzhang@njmu.edu.cn
Received: 2022-04-17
Revised: 2022-05-24
Accepted: 2022-05-27

Published: 2022-06-28

Issue Date: 2023-01-28

Abstract

Abstract

Amyotrophic lateral sclerosis (ALS) is known as a progressive paralysis disorder characterized by degeneration of upper and lower motor neurons, and has an average survival time of three to five years. Growing evidence has suggested a bidirectional link between gut microbiota and neurodegeneration. Here we aimed to report one female case with ALS, who benefited from washed microbiota transplantation (WMT), an improved fecal microbiota transplantation (FMT), through a transendoscopic enteral tube during a 12-month follow-up. Notedly, the accidental scalp trauma the patient suffered later was treated with prescribed antibiotics that caused ALS deterioration. The subsequent rescue WMTs successfully stopped the progression of the disease with a quick improvement. The plateaus and reversals occurred during the whole course of WMT. The stool and blood samples from the first WMT to the last were collected for dynamic microbial and metabolomic analysis. We observed the microbial and metabolomic changing trend consistent with the disease status. This case report for the first time shows the direct clinical evidence on using WMT for treating ALS, indicating that WMT may be the novel treatment strategy for controlling this so-called incurable disease.
- fecal microbiota transplant,
- microbiome,
- efficacy,
- neurodegeneration,
- amyotrophic lateral sclerosis

FullText(HTML)

References(23)

References

[1]	Van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis[J]. Lancet, 2017, 390(10107): 2084–2098. doi: 10.1016/S0140-6736(17)31287-4
[2]	Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis[J]. N Engl J Med, 1994, 330(9): 585–591. doi: 10.1056/NEJM199403033300901
[3]	The Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial[J]. Lancet Neurol, 2017, 16(7): 505–512. doi: 10.1016/S1474-4422(17)30115-1
[4]	Cudkowicz M, Genge A, Maragakis N, et al. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet Neurol, 2021, 20(10): 821–831. doi: 10.1016/S1474-4422(21)00242-8
[5]	Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis[J]. N Engl J Med, 2020, 383(10): 919–930. doi: 10.1056/NEJMoa1916945
[6]	Blacher E, Bashiardes S, Shapiro H, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice[J]. Nature, 2019, 572(7770): 474–480. doi: 10.1038/s41586-019-1443-5
[7]	Di Gioia D, Bozzi Cionci N, Baffoni L, et al. A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis[J]. BMC Med, 2020, 18(1): 153. doi: 10.1186/s12916-020-01607-9
[8]	Zhang Y, Ogbu D, Garrett S, et al. Aberrant enteric neuromuscular system and dysbiosis in amyotrophic lateral sclerosis[J]. Gut Microbes, 2021, 13(1): 1996848. doi: 10.1080/19490976.2021.1996848
[9]	Zhang T, Lu G, Zhao Z, et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening[J]. Protein Cell, 2020, 11(4): 251–266. doi: 10.1007/s13238-019-00684-8
[10]	Fecal Microbiota Transplantation-Standardization Study Group. Nanjing consensus on methodology of washed microbiota transplantation[J]. Chin Med J (Engl), 2020, 133(19): 2330–2332. doi: 10.1097/CM9.0000000000000954
[11]	He Z, Cui BT, Zhang T, et al. Fecal microbiota transplantation cured epilepsy in a case with Crohn's disease: the first report[J]. World J Gastroenterol, 2017, 23(19): 3565–3568. doi: 10.3748/wjg.v23.i19.3565
[12]	Liu XJ, Wu LH, Xie WR, et al. Faecal microbiota transplantation simultaneously ameliorated patient's essential tremor and irritable bowel syndrome[J]. Psychogeriatrics, 2020, 20(5): 796–798. doi: 10.1111/psyg.12583
[13]	Huang H, Xu H, Luo Q, et al. Fecal microbiota transplantation to treat Parkinson's disease with constipation: a case report[J]. Medicine (Baltimore), 2019, 98(26): e16163. doi: 10.1097/MD.0000000000016163
[14]	Huang HL, Xu HM, Liu YD, et al. First application of fecal microbiota transplantation in adult asperger syndrome with digestive symptoms-a case report[J]. Front Psychiatry, 2022, 13: 695481. doi: 10.3389/fpsyt.2022.695481
[15]	Wang J, Li Q, Huang Q, et al. Washed microbiota transplantation accelerates the recovery of abnormal changes by light-induced stress in tree shrews[J]. Front Cell Infect Microbiol, 2021, 11: 685019. doi: 10.3389/fcimb.2021.685019
[16]	Lu G, Wang W, Li P, et al. Washed preparation of faecal microbiota changes the transplantation related safety, quantitative method and delivery[J]. Microb Biotechnol, 2022, doi: 10.1111/1751-7915.14074. [Epub ahead of print].
[17]	Niccolai E, Di Pilato V, Nannini G, et al. The gut microbiota-immunity axis in ALS: a role in deciphering disease heterogeneity?[J]. Biomedicines, 2021, 9(7): 753. doi: 10.3390/biomedicines9070753
[18]	Hertzberg VS, Singh H, Fournier CN, et al. Gut microbiome differences between amyotrophic lateral sclerosis patients and spouse controls[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2022, 23(1-2): 91–99. doi: 10.1080/21678421.2021.1904994
[19]	Rowin J, Xia Y, Jung B, et al. Gut inflammation and dysbiosis in human motor neuron disease[J]. Physiol Rep, 2017, 5(18): e13443. doi: 10.14814/phy2.13443
[20]	Bedlack RS, Vaughan T, Wicks P, et al. How common are ALS plateaus and reversals?[J]. Neurology, 2016, 86(9): 808–812. doi: 10.1212/WNL.0000000000002251
[21]	Van Eijk RPA, Van Den Berg LH. Comment: Plateaus and reversals in ALS disease course or limitations of trial design?[J]. Neurology, 2016, 86(9): 811. doi: 10.1212/WNL.0000000000002365
[22]	Cox LM, Calcagno N, Gauthier C, et al. The microbiota restrains neurodegenerative microglia in a model of amyotrophic lateral sclerosis[J]. Microbiome, 2022, 10(1): 47. doi: 10.1186/s40168-022-01232-z
[23]	Mandrioli J, Amedei A, Cammarota G, et al. FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis[J]. Front Neurol. 2019, 10: 1021.